Genetics and mental health, Manufacturing and Personality disorders

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Genetics and mental health

Manufacturing

Personality disorders

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

JULY 1, 2025

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.”

Genetics and mental health

Genetics and mental health Bipolar disorder Sleep and mental health Aging and mental health

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

JUNE 23, 2025

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. 1 The company has previously filed the required Chemistry, Manufacturing, and Controls (CMC) information and received FDA feedback.

Pharmaceuticals

Pharmaceuticals Bipolar disorder Genetics and mental health Manufacturing

Mental Health Clinicians

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Stay Connected